Skip to main content
Elsevier
View Cart
My account

Books in Hematology

BooksJournals

    • Hodgkin’s Lymphoma, An Issue of Hematology/Oncology Clinics

      • 1st Edition
      • Volume 28-1
      • December 2, 2013
      • Volker Diehl
      • English
      • Hardback
        9 7 8 0 3 2 3 2 6 6 6 0 4
      • eBook
        9 7 8 0 3 2 3 2 6 6 6 1 1
      This issue of Hematology/Oncology Clinics is focused on Hodgkin's Lymphoma and covers such topics as First HRS-cell line L428 and the detection of the CD-30 Antigen , “Normal“ CD30-B-lymphocytes, CD-30-Antigen, Combination-Chemo-Ra... Early intensification (escBEACOPP), Customized/Targeted Therapy, and more.

    • Haematology

      • 4th Edition
      • May 30, 2013
      • Martin R. Howard + 1 more
      • English
      • Paperback
        9 7 8 0 7 0 2 0 5 1 3 9 5
      • eBook
        9 7 8 0 7 0 2 0 5 4 1 5 0
      • eBook
        9 7 8 0 7 0 2 0 5 6 8 8 8
      2014 BMA Medical Book Awards Highly Commended in Internal Medicine category! This textbook on haematology in the Illustrated Colour Text series is suitable for medical students, junior doctors and others needing a concise and practical introduction to the subject.

    • Molecular Pathology, An Issue of Clinics in Laboratory Medicine

      • 1st Edition
      • Volume 33-4
      • December 2, 2013
      • Martin H. Bluth
      • English
      • Hardback
        9 7 8 0 3 2 3 2 6 1 0 4 3
      • eBook
        9 7 8 0 3 2 3 2 6 1 0 5 0
      Molecular pathology has significantly matured over the past decade to establish itself as a discipline in its own right. Patient diagnosis, prognosis, management and care have been influenced by molecular pathology testing algorithms on a global scale. Whether it pertains to carrier status of deleterious genes, diagnosis by molecular techniques, assessment of appropriate remission post treatment, parentage or forensics testing – molecular pathology continues to increase its presence and influence in the diagnostic laboratory armamentarium. Furthermore, intellectualization and proprietization of molecular pathology with respect to the discovery of new genes and or new techniques continues to pose new challenges of test ownership, legalities, liabilities, widespread acceptance and utility. This issue of Laboratory Clinics seeks to provide selective state of the art understanding of molecular pathology with respect to its relationship to key pathology disciplines as well as the current challenges and promise for the future

    • Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

      • 1st Edition
      • Volume 27-2
      • April 23, 2013
      • Jennifer R. Brown
      • English
      • Hardback
        9 7 8 1 4 5 5 7 7 1 0 1 1
      • eBook
        9 7 8 1 4 5 5 7 7 1 8 8 2
      This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments,Wh... is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 in CLL, and Evolving Role of Stem Cell Transplantation in CLL.

    • Quality Control in the age of Risk Management, An Issue of Clinics in Laboratory Medicine

      • 1st Edition
      • Volume 33-1
      • January 28, 2013
      • James O. Westgard + 1 more
      • English
      • Hardback
        9 7 8 1 4 5 5 7 7 1 1 0 3
      • eBook
        9 7 8 1 4 5 5 7 7 2 3 1 5
      In October of 2011, CLSI published a new guideline EP23A on “Laboratory Quality Control Based on Risk Management.” In March, 2012, CMS announced its intention to incorporate key concepts from EP23A into its Interpretative Guidelines and QC policy for “Individualized Quality Control Plans.” Thus begins a new era of Quality Control in the Age of Risk Management. This issue is intended to help laboratories with the transition between traditional QC practices and the new risk management approach. Laboratories face a steep learning curve to apply risk analysis for identifying and prioritizing failure-modes, developing and implementing control mechanisms to detect those failure-modes, and assessing the acceptability of the residual risks that exist after implementation of a QC Plan. One of the main benefits of the new risk analysis based QC Plans should be an integration of all the control mechanisms that are needed to monitor the total testing process, including pre-analytic, analytic, and post-analytic controls. One of the main risks of the new approach is an expectation that Statistical QC is no longer important, even though SQC still remains the most useful and flexible approach for monitoring the quality of the analytic process. The key to the future is the successful integration of all these control mechanisms to provide a cost-effective quality system that monitors all phases of the total testing process. This issue should help laboratories understand the evolution of QC practices to include risk management, but also to recognize the need to maintain traditional techniques such as Statistical QC, especially during the transition to well-designed and carefully-validated QC Plans. Risk analysis may be risky business unless laboratories proceed carefully and cautiously.

    • Disorders of the Platelets, An Issue of Hematology/Oncology Clinics of North America

      • 1st Edition
      • Volume 27-3
      • June 20, 2013
      • Koneti Rao
      • English
      • Hardback
        9 7 8 1 4 5 5 7 7 1 0 2 8
      • eBook
        9 7 8 1 4 5 5 7 7 1 8 9 9
      This issue of Hematology/Oncology Clinics is guest edited by Dr. A. Koneti Rao and focuses on Disorder of the Platelets. Article titles include: Mechanisms of Platelet Activation and Inhibition, Testing Platelet Function,Clinical Implications of Platelet Genomics and Proteomics, Congenital Thrombocytopenias, Immune Thrombocytopenias, Heparin Induced Thrombocytopenia, and Functional defects: Chronic granulomatous disease (CGD) and beyond.

    • Prostate Cancer, An Issue of Hematology/Oncology Clinics of North America

      • 1st Edition
      • Volume 27-6
      • November 12, 2013
      • Christopher Sweeney
      • English
      • Hardback
        9 7 8 0 3 2 3 2 2 7 2 2 3
      • eBook
        9 7 8 0 3 2 3 2 2 7 2 3 0
      This issue of Hematology/Oncology Clinics is focused on Prostate Cancer and highlights topics such as: Prevention, Early Detection, Biomarkers, Risk stratification, Imaging in Prostate Cancer, Adjuvant hormonal therapy, Management of patient with biochemical relapse, Management of patient with newly metastatic disease, and Bone Health Management.

    • Neutropenia, An Issue of Hematology/Oncology Clinics of North America

      • 1st Edition
      • Volume 27-1
      • February 28, 2013
      • English
      • Hardback
        9 7 8 1 4 5 5 7 7 1 0 0 4
      • eBook
        9 7 8 1 4 5 5 7 7 1 8 7 5
      This issue of Hematology/Oncology Clinics is guest edited by Dr. Christoph Klein and focuses on the topic of Neutropenia. Article titles include: Homeostasis and migration of neutrophil granulocytes,Granulo... Stimulating Factor (G-CSF) receptor signaling,New Granulocyte-colony Stimulating Factor (G-CSF) Receptor Signaling Pathways ,Neutrophil elastase (ELANE) – Genetics and Pathophysiology,Auto... recessive variants of Severe congenital neutropenia (SCN),Leukocyte Adhesion Deficiency (LAD), and Genotype-phenotype correlations in Severe congenital neutropenia (SCN).

    • Sarcoma, An Issue of Hematology/Oncology Clinics of North America

      • 1st Edition
      • Volume 27-5
      • October 15, 2013
      • Andrew J. Wagner
      • English
      • Hardback
        9 7 8 0 3 2 3 2 6 1 0 0 5
      • eBook
        9 7 8 0 3 2 3 2 6 1 0 1 2
      This issue focuses on Sarcoma in areas such as: Gastrointestinal Stromal Tumors: Risk assessment and adjuvant therapy, Gastrointestinal Stromal Tumors: Management of metastatic disease and emerging therapies, Liposarcoma, Leiomyosarcoma, Update in treatment and targets in cartilage and bone tumors, Update in treatment and targets in Ewing sarcoma, Angiosarcoma and Epithelioid Hemangioendothelioma... Emerging therapies for sarcoma, and Treatment of localized sarcomas.

    • New Drugs for Malignancy, An Issue of Hematology/Oncology Clinics of North America

      • 1st Edition
      • Volume 26-3
      • May 8, 2012
      • Franco Muggia
      • English
      • Hardback
        9 7 8 1 4 5 5 7 3 8 7 6 2
      • eBook
        9 7 8 1 4 5 5 7 4 4 0 8 4
      Topics in this issue include: Targeting IGF-1R; Tyrosine Kinase Inhibitors in Lung Cancer; Targeting mTOR; Targeting Hedgehog; Mitotic Inhibitors; Topoisomerase I Inhibitors; and New Strategies and Drugs Inhibiting Folate Pathways.